Three months treatment of active spondyloarthritis with imatinib mesylate: An open-label pilot study with six patients [3]

Rheumatology

Volumn 45, Issue 12, 2006, Pages 1573-1575

  Eklund, Kari K ^a   Remitz, A ^a   Kautiainen, H ^b   Reitamo, S ^a   Leirisalo Repo, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HLA B27 ANTIGEN; IMATINIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ANTIGEN DETECTION; ANTIINFLAMMATORY ACTIVITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG ERUPTION; HUMAN; LETTER; LEUKOPENIA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; SINUSITIS; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT FAILURE; VISUAL ANALOG SCALE;

ADULT; ANTIRHEUMATIC AGENTS; HUMANS; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TREATMENT OUTCOME;

EID: 33751408283     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel365     Document Type: Letter

References (8)

1. Kindler T, Breitenbuecher F, Marx A et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004;103:3644-54.
2. Dewar AL, Cambareri AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105:3127-32.
3. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Ann Med 2003;35:362-7.
4. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003;22:329-32.
5. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
6. Mander M, Simpson JM, McLellan A, Walker D, Goodcare JA, Dick WC. Studies with enthesis index as a method for clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
7. Juurikivi A, Sandler C, Lindstedt K et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: A potential approach to the treatment of arthritis. Ann Rheum Dis 2005;64:1126-31.
8. Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2006;347:31-5.